Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma

Summary

The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.

Timeline

Start

2019-08-28

Primary completion

2020-10-19

Completion

2021-02-01

Outcome

Outcome not reported

Stopped: “An interim analysis run by an independent data monitoring committee (DMC) to assess futility met the protocol-defined futility rules. The DMC recommended to stop the study for futility. The Sponsor issued a notification of early study termination.”

Drugs

Indications